1. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. (1st December 2016) Authors: Virabhak, Suchin; Yasui, Kikuo; Yamazaki, Kiyotaka; Johnson, Scott; Mitchell, Dominic; Yuen, Cammy; Samp, Jennifer C.; Igarashi, Ataru Journal: Journal of medical economics Issue: Volume 19:Number 12(2017) Page Start: 1144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Global timing of hepatitis C virus elimination in high‐income countries. (23rd December 2019) Authors: Razavi, Homie; Sanchez Gonzalez, Yuri; Yuen, Cammy; Cornberg, Markus Journal: Liver international Issue: Volume 40:Number 3(2020) Page Start: 522 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. (24th April 2020) Authors: Razavi, Homie; Gonzalez, Yuri Sanchez; Yuen, Cammy; Cornberg, Markus Journal: Liver international Issue: Volume 40:Number 6(2020) Page Start: 1507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗